Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
2. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol
3. Bms 512148
4. Bms-512148
5. Bms512148
6. Dapagliflozin
7. Farxiga
8. Forxiga
1. 960404-48-2
2. Dapagliflozin Propanediol Monohydrate
3. Dapagliflozin Propanediol Hydrate
4. Farxiga
5. Dapagliflozin ((2s)-1,2-propanediol, Hydrate)
6. Bms-512148-05
7. Dapagliflozin S-propylene Glycol Monohydrate
8. Dapagliflozin Propylene Glycolate Hydrate
9. Chebi:85079
10. Dapagliflozin Propanediol [usan]
11. Dapagliflozin Mixture With Propylene Glycol, Hydrate
12. 887k2391vh
13. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2s)-propane-1,2-diol;hydrate
14. Dapagliflozin [usan:inn]
15. Dapagliflozin Propylene Glycol Hydrate
16. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol Compound With (s)-propane-1,2-diol (1:1) Hydrate
17. D-glucitol, 1,5-anhydro-1-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1s)-, Compd. With (2s)-1,2-propanediol, Hydrate (1:1:1)
18. Unii-887k2391vh
19. Dapagliflozin Propylene Glycolate Hydrate [jan]
20. Dapagliflozin (s)-propylene Glycol Hydrate
21. Chembl2103802
22. Dtxsid00914678
23. Ex-a2824
24. Dapagliflozin Propylene Glycol
25. Hy-10450a
26. Mfcd28167768
27. S5566
28. Akos027250601
29. Ccg-269711
30. Ac-29230
31. As-64915
32. Dapagliflozin (2s)-1,2-propanediol Hydrate
33. F20667
34. Bms-512148 (2s)-1,2-propanediol, Hydrate
35. Dapagliflozin (2s)-1,2-propanediol Monohydrate
36. Xigduo Component Dapagliflozin Propanediol
37. A900162
38. Dapagliflozin Propanediol Component Of Xigduo
39. Dapagliflozin Propanediol Monohydrate [who-dd]
40. Q27158320
41. Dapagliflozin Propanediol Monohydrate [ema Epar]
42. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate
43. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate [mi]
44. (2s)-propane-1,2-diol (2s,3r,4r,5s,6r)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol Hydrate
45. (2s)-propane-1,2-diol--(1s)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-d-glucitol--water (1/1/1)
46. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro- 2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
47. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol (s)-propane-1,2-diol Hydrate
48. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
49. 1700615-13-9
Molecular Weight | 503.0 g/mol |
---|---|
Molecular Formula | C24H35ClO9 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 7 |
Exact Mass | 502.1969604 g/mol |
Monoisotopic Mass | 502.1969604 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 493 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied.
Heart failure
- Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
- Forxiga is indicated in adults for the treatment of chronic kidney disease.
Type 2 diabetes mellitus
Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Heart failure
Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
Edistride is indicated in adults for the treatment of chronic kidney disease.
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
A10BK01
A10BK01
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-07-16
Pay. Date : 2018-12-20
DMF Number : 33387
Submission : 2018-12-30
Status : Active
Type : II
Available Reg Filing : ASMF |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33026
Submission : 2018-08-14
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm :
NDC Package Code : 71796-006
Start Marketing Date : 2018-08-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Poonglim Pharmaceutical Co., Ltd.
Registration Date : 2022-11-24
Registration Number : No. 574-16-ND(1)
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTO-SEZ Process Unit-01, Sector No’s. 28 to 34, 36 to 37, 40, 50 to 53 & 03 Survey No' s. 57 to 58, 60, 72 to 73, 76 to 77 & 80 Devunipalavalasa Village, Ranastalam Mandal, Srikakulam District-532 409, Andhra Pradesh, India
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36048
Submission : 2021-06-28
Status : Active
Type : II
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-037
Start Marketing Date : 2021-06-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
Soujanya Life Sciences makes API & intermediates for various therapeutic categories including Antidiabetic, Anti-Hypertensive, etc.
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34235
Submission : 2019-10-15
Status : Active
Type : II
Date of Issue : 2022-08-25
Valid Till : 2025-07-02
Written Confirmation Number : WC-0195
Address of the Firm :
NDC Package Code : 76072-1014
Start Marketing Date : 2019-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2020-10-13
Registration Number : 434-24-ND
Manufacturer Name : ZCL Chemicals Limited
Manufacturer Address : 3102/B GIDC, Industrial Estate Ankleshwar City : Ankleshwar-393 002, Dist : Bharuch, Gujarat state, India
Available Reg Filing : CN |
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?